ARTICLES BY WALTER COLASANTE
-
![Asain Woman Scientist]( "How Are Cell And Gene Therapies Changing Drug Development Models?")
How Are Cell And Gene Therapies Changing Drug Development Models?7/12/2018A range of factors — including small patient populations, complex manufacturing processes, and lack of specialized expertise — are positioned to both drive up costs and require new options for stakeholder engagement and risk sharing along the development pathway. New approaches in development are needed to support the next generation of novel drugs on the horizon.
-
![puzzle_of_dollar_bill]( "What’s The Right Pricing Strategy For Cell And Gene Therapies?")
What’s The Right Pricing Strategy For Cell And Gene Therapies?5/15/2018This article highlights the diverse interests and range of opinions about pricing innovative and often high-cost therapies, but also demonstrates that most players in the sector see an urgent need for new pricing models to accommodate cell and gene therapy products.
Walter Colasante
Walter Colasante is VP in CRA’s Life Sciences Practice. He has experience in both the pharmaceutical and consulting industries and across a range of different therapeutic areas including oncology, the central nervous system, and rare diseases.